NCT06039917 Effect of the Automatic Surveillance System on Surveillance Rate of Patients with Gastric Premalignant Lesions
| NCT ID | NCT06039917 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Renmin Hospital of Wuhan University |
| Condition | Artificial Intelligence |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,460 participants |
| Start Date | 2023-09-10 |
| Primary Completion | 2028-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 1,460 participants in total. It began in 2023-09-10 with a primary completion date of 2028-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In this study, we proposed a prospective study about the effect of the automatic surveillance system on surveillance rate of patients with gastric premalignant lesions. The enrolled patients were divided into group A with intelligent surveillance system, group B with manual reminder, and group C with natural state. The surveillance among the three groups will be compared.
Eligibility Criteria
Inclusion Criteria: * Male or female aged 18 years or older who undergo upper endoscopy. Exclusion Criteria: * 1)No contact information or invalid contact information. * 2\) The surveillance interval cannot be determined according to the surveillance guidelines, including no upper gastrointestinal pathology, therapeutic endoscopy or with history of previous gastrectomy, esophagectomy, or ESD, no dysplasia degrees, no biopsy sites, non-epithelial lesions, duodenal lesions, ulcer and so on. * 3\) Needless for surveillance or others. * 4\) High-grade intraepithelial neoplasia or cancer of the esophagus or stomach. * 5\) Low-grade intraepithelial neoplasia of the esophagus and Barrett's esophagus. * 6\) High-risk diseases or other special conditions for which the patient is deemed unsuitable for clinical trials by the investigator.
Contact & Investigator
Honggang Yu, PhD
PRINCIPAL INVESTIGATOR
Renmin Hospital of Wuhan University
Frequently Asked Questions
Who can join the NCT06039917 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Artificial Intelligence. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06039917 currently recruiting?
Yes, NCT06039917 is actively recruiting participants. Contact the research team at yuhonggang1968@163.com for enrollment information.
Where is the NCT06039917 trial being conducted?
This trial is being conducted at Quanzhou, China, Wuhan, China, Wuhan, China, Shanghai, China.
Who is sponsoring the NCT06039917 clinical trial?
NCT06039917 is sponsored by Renmin Hospital of Wuhan University. The principal investigator is Honggang Yu, PhD at Renmin Hospital of Wuhan University. The trial plans to enroll 1,460 participants.